Quest’s First Pooled Sample COVID-19 Diagnostic Test Could Save Time, Resources: FDA
Executive Summary
US regulators gave the thumbs-up to the first COVID-19 test that pools patient samples to determine if any one of the individuals in the pool may be infected. Despite concerns such tests may be diluted and make it harder to detect the SARS-CoV-2 virus, the FDA says validation data shows it works.
You may also be interested in...
Some COVID-19 Molecular Diagnostics Can Skip Forward To Market For Pooled Screening
The US FDA says as long as the EUA-authorized tests provide a notification with validation data and procedural information, they can be used for pooled serial screening before additional review.
FDA Greenlights Second Pooled Sample COVID-19 Test As Crucial Tool To Reopen US Economy
US regulators have re-issued an EUA to LabCorp’s COVID-19 molecular diagnostic test for pooled sampling. While the method could speed up testing and use less resources, it also can result in false negatives.
COVID-19 Fact File: Global Diagnostic Test Pipeline
Medtech Insight is tracking the IVD companies manufacturing tests for SARS-CoV-2, the coronavirus that causes COVID-19.